Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: KLF6

Summary for KLF6

Gene information	Gene symbol	KLF6
	Ensembl ID	ENSG00000067082
	Entrez ID	1316
	Gene name	KLF transcription factor 6
	Synonyms	BCD1\|COPEB\|CPBP\|GBF\|PAC1\|ST12\|Zf9
	Gene type	protein_coding
	UniProtAcc	Q99612

Top

Dataset with differentially expressed gene: KLF6

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.339492	2.47e-07
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.293309	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.554595	9.02e-25
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.668301	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.266555	1.21e-27
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	1.12935	4.27e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.569895	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.522189	9.68e-09
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.656629	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	1.17311	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.519187	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.529929	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.3092	1.17e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	1.10231	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.706014	4.43e-43
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.961986	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.46354	7.36e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	1.19353	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.93527	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.269846	9.82e-23
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.297773	3.48e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.369628	4.35e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	0.418952	2.96e-18
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.75123	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.353659	9.87e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.370261	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.434871	2.28e-02
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.571454	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	-0.303358	2.02e-13
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.947719	5.66e-04
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.19645	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.4438	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	B cells	-0.276543	5.09e-10
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.478503	4.22e-02
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	-0.530182	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	-0.435975	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.470097	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	1.18538	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	1.75519	7.23e-40
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.641104	4.05e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.07014	1.44e-23
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.942837	7.35e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.61577	1.01e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.466364	7.61e-09
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	0.295621	5.22e-23
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.461857	9.35e-07
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.689013	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.472657	1.52e-31
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	0.598726	3.42e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.434981	8.26e-22
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.84485	1.96e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.568252	1.38e-09
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	-0.727683	3.37e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.353495	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.493766	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.314454	3.75e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.542767	4.38e-17
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.660025	1.29e-02
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.421669	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.301498	1.39e-22
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.462305	8.54e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.474128	3.93e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.509826	4.34e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.492278	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.540247	1.98e-15
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	1.05938	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.805312	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.595023	2.45e-29
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.587512	2.65e-05
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.487876	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	-0.494602	1.65e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.690271	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.555302	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.579122	1.49e-06
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-0.760108	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.629357	6.03e-21
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.710195	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.429634	1.31e-16
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.396966	9.81e-42

Top

Expression of KLF6 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to KLF6

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating KLF6

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
KLF6	hsa-miR-5011-5p	99.9991	NM_001160125
KLF6	hsa-miR-3148	99.9276	NM_001160125
KLF6	hsa-miR-190a-3p	99.9139	NM_001160125
KLF6	hsa-miR-8485	99.4487	NM_001160125
KLF6	hsa-miR-651-3p	98.5836	NM_001160125
KLF6	hsa-miR-4263	98.4675	NM_001160125
KLF6	hsa-miR-6124	98.4306	NM_001160125
KLF6	hsa-miR-498-5p	98.3966	NM_001160125
KLF6	hsa-miR-4521	97.7342	NM_001160125
KLF6	hsa-miR-12136	97.0642	NM_001160125
KLF6	hsa-miR-6797-3p	96.6123	NM_001160125
KLF6	hsa-miR-3612	96.5909	NM_001160125
KLF6	hsa-miR-650	96.5909	NM_001160125
KLF6	hsa-miR-4742-3p	96.52	NM_001160125
KLF6	hsa-miR-10527-5p	96.4368	NM_001160125
KLF6	hsa-miR-767-5p	96.0791	NM_001160125
KLF6	hsa-miR-520d-5p	96.0778	NM_001160125
KLF6	hsa-miR-524-5p	96.0778	NM_001160125
KLF6	hsa-miR-6076	95.9225	NM_001160125
KLF6	hsa-miR-2467-5p	94.1438	NM_001160125
KLF6	hsa-miR-4687-5p	93.8548	NM_001160125
KLF6	hsa-miR-5093	93.7924	NM_001160125
KLF6	hsa-miR-4262	93.4585	NM_001160125
KLF6	hsa-miR-148b-3p	92.865	NM_001160125
KLF6	hsa-miR-148a-3p	92.865	NM_001160125
KLF6	hsa-miR-152-3p	92.865	NM_001160125
KLF6	hsa-miR-607	92.7049	NM_001300
KLF6	hsa-miR-9851-3p	92.4208	NM_001160125
KLF6	hsa-miR-593-5p	92.4208	NM_001160125
KLF6	hsa-miR-3622b-3p	92.3965	NM_001300
KLF6	hsa-miR-3622a-3p	92.3965	NM_001300
KLF6	hsa-miR-513a-5p	92.3433	NM_001160125
KLF6	hsa-miR-362-3p	92.1606	NM_001160125
KLF6	hsa-miR-181d-5p	91.604	NM_001160125
KLF6	hsa-miR-181b-5p	91.604	NM_001160125
KLF6	hsa-miR-181a-5p	91.604	NM_001160125
KLF6	hsa-miR-181c-5p	91.604	NM_001160125
KLF6	hsa-miR-548at-5p	91.3812	NM_001300
KLF6	hsa-miR-22-3p	90.7947	NM_001160125
KLF6	hsa-miR-3926	90.7315	NM_001160125
KLF6	hsa-miR-543	90.7194	NM_001160125
KLF6	hsa-miR-6830-5p	90.3314	NM_001160125
KLF6	hsa-miR-4430	90.0145	NM_001160125
KLF6	hsa-miR-3652	90.0145	NM_001160125
KLF6	hsa-miR-1207-5p	89.4006	NM_001160125
KLF6	hsa-miR-329-3p	89.3746	NM_001160125
KLF6	hsa-miR-603	89.3746	NM_001160125
KLF6	hsa-miR-200a-3p	88.8222	NM_001160125
KLF6	hsa-miR-141-3p	88.8222	NM_001160125
KLF6	hsa-miR-515-5p	88.6148	NM_001300

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating KLF6

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
KLF6	hdpi__PQBP1	PQBP1 (directAnnotation).
KLF6	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_1	SPIB; TEAD4 (directAnnotation).
KLF6	transfac_pro__M04856	BATF (directAnnotation).
KLF6	transfac_pro__M04846	MEF2C (directAnnotation).
KLF6	tfdimers__MD00021	NFATC3; ZBTB7A (directAnnotation).
KLF6	kznf__ZNF480_Imbeault2017_OM_RCADE	ZNF480 (directAnnotation).
KLF6	metacluster_29.1	STAT4; STAT5A; STAT5A; STAT5B (directAnnotation). STAT5B; STAT5B (inferredBy_Orthology).
KLF6	transfac_pro__M06678	ZNF287 (inferredBy_Orthology).
KLF6	transfac_pro__M06062	ZNF623 (directAnnotation).
KLF6	tfdimers__MD00581	ATF5; NKX3-2 (directAnnotation).
KLF6	metacluster_79.34	GATA2; GATA5 (directAnnotation).
KLF6	metacluster_82.6	ZNF211 (directAnnotation).
KLF6	hdpi__NFATC3	NFATC3 (directAnnotation).
KLF6	transfac_pro__M05744	ZXDC (directAnnotation).
KLF6	swissregulon__mm__Zbtb12	ZBTB12 (inferredBy_Orthology).
KLF6	transfac_pro__M01239	RELA (directAnnotation).
KLF6	metacluster_79.36	BRCA1 (directAnnotation).
KLF6	tfdimers__MD00029	IKZF2; NKX3-2 (directAnnotation).
KLF6	transfac_pro__M06232	ZNF234 (directAnnotation).
KLF6	transfac_pro__M02191	SOX17 (inferredBy_Orthology).
KLF6	transfac_pro__M06035	ZNF749 (directAnnotation).
KLF6	cisbp__M07938	E2F1 (directAnnotation).
KLF6	kznf__ZNF90_Imbeault2017_OM_RCADE	ZNF90 (directAnnotation).
KLF6	taipale_cyt_meth__E2F2_NCGCGCGCGCM_eDBD_meth	E2F2 (directAnnotation).
KLF6	kznf__ZNF2_Imbeault2017_RP_ChIP-seq	ZNF2 (directAnnotation).
KLF6	jaspar__MA1951.1	FOS (directAnnotation).
KLF6	transfac_pro__M05672	ZNF133 (directAnnotation).
KLF6	metacluster_63.4	ZNF672 (directAnnotation).
KLF6	transfac_pro__M04933	STAT3 (directAnnotation).
KLF6	metacluster_174.6	NFYA; NFYB; NFYB; NFYC (directAnnotation).
KLF6	transfac_public__M00040	ATF2 (directAnnotation).
KLF6	metacluster_32.25	ZNF287 (directAnnotation).
KLF6	transfac_pro__M05601	FIZ1 (directAnnotation).
KLF6	transfac_pro__M01081	ZNF628 (directAnnotation).
KLF6	transfac_pro__M06573	ZNF419 (directAnnotation).
KLF6	taipale_tf_pairs__ETV2_DLX3_RSCGGAANNNNNNNTAATKR_CAP_repr	DLX3; ETV2 (directAnnotation).
KLF6	hdpi__NRL	NRL (directAnnotation).
KLF6	flyfactorsurvey__Mad_FlyReg_FBgn0011648	SMAD9 (inferredBy_Orthology).
KLF6	transfac_pro__M07310	SP5 (directAnnotation).
KLF6	metacluster_67.2	ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology).
KLF6	transfac_pro__M02089	E2F3 (directAnnotation).
KLF6	transfac_pro__M02933	ZBTB14 (inferredBy_Orthology).
KLF6	tfdimers__MD00483	ZBTB14 (directAnnotation).
KLF6	transfac_pro__M00716	ZBTB14 (directAnnotation).
KLF6	transfac_pro__M03806	ZBTB7C (directAnnotation).
KLF6	jaspar__MA0535.1	SMAD9 (inferredBy_Orthology).
KLF6	transfac_pro__M04916	TAF1 (directAnnotation).
KLF6	jaspar__MA1650.1	ZBTB14 (directAnnotation).
KLF6	cisbp__M08228	PAX5 (directAnnotation).
KLF6	metacluster_24.1	HIC1; HIC1; ZNF816; ZNF816; ZNF816; ZXDC (directAnnotation).

Page: 1 2 3 4 5 6 7 8 9

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
KLF6	transfac_pro__M07461	down	Malignant cells	GSE138267	NA
KLF6	metacluster_195.2	up	Malignant cells	GSE152469	NA
KLF6	metacluster_163.1	down	Malignant cells	GSE153697	NA
KLF6	metacluster_163.1	up	Malignant cells	GSE161801_IMiD	pre
KLF6	metacluster_163.1	down	B cells	GSE169246_PacAteTissue	post
KLF6	transfac_pro__M07461	down	B cells	GSE169246_PacAteTissue	post
KLF6	metacluster_195.2	down	B cells	GSE169246_PacAteTissue	post
KLF6	swissregulon__hs__KLF6	up	CD4+ T cells	GSE169246_PacBlood	pre
KLF6	metacluster_195.2	up	B cells	GSE169246_PacTissue	pre
KLF6	swissregulon__hs__KLF6	up	CD4+ T cells	GSE169246_PacTissue	pre
KLF6	metacluster_195.2	up	Malignant cells	GSE189460	pre
KLF6	swissregulon__hs__KLF6	up	Malignant cells	GSE189460	pre
KLF6	metacluster_195.2	down	Malignant cells	GSE199333	pre
KLF6	metacluster_163.1	down	Malignant cells	GSE199333	pre

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."